Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 16/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205697 | 0.89 | NAMPT (0.48) | NAMPTCYP3A4CYP2C9ACHEBCHE | |
| SCHEMBL24947604 | 0.80 | NAMPT (0.67) | NAMPTCYP3A4CYP2C9ACHEBCHE | |
| SCHEMBL21060370 | 0.78 | NAMPT (0.71) | NAMPTCYP3A4CYP2C9ACHEBCHE | |
| SCHEMBL19317565 | 0.76 | NAMPT (0.82) | NAMPTCYP3A4CYP2C9ACHEBCHE | |
| SCHEMBL19834837 | 0.70 | NAMPT (0.65) | NAMPTCYP3A4CYP2C9ACHEBCHE | |
| Daporinad SCHEMBL156944 | 0.70 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9 | |
| Daporinad SCHEMBL82367 | 0.70 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL19834849 | 0.70 | NAMPT (0.80) | NAMPTCYP3A4CYP2C9ACHEBCHE | |
| Daporinad SCHEMBL31181445 | 0.70 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9 | |
| Daporinad SCHEMBL82368 | 0.70 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023007147-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | THE UNIVERSITY OF MANCHESTER (GB) | 2023-02-02 | — | — | WO | disclosed |